Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

LLantern Pharma Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
L

Lantern Pharma Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
    Sep 23, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
    Sep 22, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
    Sep 17, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
    Aug 14, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
    Aug 7, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
    Aug 3, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
    Jul 28, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
    Jul 23, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
    Jul 8, 2026Lantern Pharma Inc Press Releases
  • Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
    Jun 2, 2026Lantern Pharma Inc Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$1.36Close · Sep 22, 2026